OSCR
Oscar Health, Inc.
OSCR has the edge over SNWV overall, supported by stronger fundamentals.
SNWV
SANUWAVE Health Inc.
SNWV trails on the overall score without a compensating advantage in the available component scores.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
SNWV Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Healthy | |
| Strong |
SNWV's cash flow and balance sheet are currently healthy, and its profitability is stable, but its revenue is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over SNWV in the historical PE scenario, which offers more potential upside but is not a forecast.
SNWV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 1.2x | $1.58 | — |
| Current | 4.3x | $1.58 | — |
| Cheap | 4.4x | $1.63 | +3.2% |
| Fair | 4.9x | $1.81 | +15% |
| Expensive | 5.7x | $2.10 | +33% |
Historical ranges are pointers, not guarantees.
SNWV's PE is 4.3x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over SNWV on the outlook, with more favorable revenue expectations.
SNWV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect SNWV's earnings to grow and its profitability to improve, but its revenue to decline.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus SNWV down 90%.
SNWV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.28 | +247% |
| Q3 2024 | $4.76 | +$31.01 |
| Q2 2024 | $0.00 | +$15.00 |
| Q1 2024 | -$3.75 | +$7.50 |
| Q4 2023 | -$11.25 | -$3.75 |
| Q3 2023 | -$26.25 | -$18.75 |
| Q2 2023 | -$15.00 | -$3.75 |
| Q1 2023 | -$11.25 | +$7.50 |
| Q4 2022 | -$7.50 | +$11.25 |
SNWV has returned to profit: it earned $0.37 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over SNWV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over SNWV on profitability, with a higher operating margin.
SNWV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.6M | -25% |
| Q2 2026 | $9.7M | -4.2% |
| Q1 2026 | $9.6M | +3% |
| Q4 2025 | $13.4M | +30% |
| Q3 2025 | $11.5M | +22% |
| Q2 2025 | $10.2M | +42% |
| Q1 2025 | $9.3M | +61% |
| Q4 2024 | $10.3M | +48% |
SNWV's revenue has held roughly level: $9M last quarter, down 25% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | -25 points |
| Q2 2026 | -2.9% | -21 points |
| Q1 2026 | -12% | -22 points |
| Q4 2025 | 15% | -9.5 points |
| Q3 2025 | 13% | -8.1 points |
| Q2 2025 | 18% | -9.3 points |
| Q1 2025 | 11% | +29 points |
| Q4 2024 | 24% | +9.6 points |
SNWV's operating margin was −13% last quarter, down 25 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over SNWV on cash flow, with more consistent year-over-year improvement.
SNWV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -296% |
| Q2 2026 | $91K | +$257K |
| Q1 2026 | $374K | +$2.1M |
| Q4 2025 | $3.2M | +538% |
| Q3 2025 | $556K | -55% |
| Q2 2025 | -$166K | +$594K |
| Q1 2025 | -$1.7M | -270% |
| Q4 2024 | $505K | +$1.8M |
SNWV's free cash flow has turned positive after six years mostly in the red: $3M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
SNWV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +1.1K shares |
| 1 year | -5.9% | -538K shares |
| 3 years | +487% | +7.1M shares |
| 5 years | +739% | +7.6M shares |
SNWV has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
SNWV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -8.0x | Net Cash |
| Q2 2026 | -2.8x | Net Cash |
| Q1 2026 | 1.9x | Healthy |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | -1.0x | Net Cash |
| Q1 2025 | -1.0x | Net Cash |
| Q3 2024 | 0.9x | Very low |
SNWV has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
SNWV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.2 | Oversold |
| Stochastic | 16.7 | Oversold |
SNWV's weekly RSI is 24 (oversold) and its Stochastic is 17 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SNWV PE vs Healthcare Sector
| Metric | SNWV | Sector median | Relative |
|---|---|---|---|
| PE | 4.3x | 26x | 83% below |
| PE % | 12 | 29 | 17 pts below |
SNWV has the edge over OSCR on valuation relative to its sector.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over SNWV on trend strength, trading above more of its moving averages.
SNWV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.32 | 63% below |
| 20 week MA | $5.42 | 71% below |
| 50 week MA | $15.2 | 90% below |
| 100 week MA | $23.5 | 93% below |
| 200 week MA | $16.3 | 90% below |
SNWV is in a downtrend: it's below all five of its weekly moving averages, and 90% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over SNWV on returns for 2026, with the stronger performance.
SNWV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.9 | $79.7 | +29% |
| 2021 | $79.7 | $56.3 | -29% |
| 2022 | $56.3 | $10.5 | -81% |
| 2023 | $10.5 | $4.87 | -54% |
| 2024 | $4.87 | $23.0 | +371% |
| 2025 | $23.0 | $30.5 | +33% |
| 2026 YTD | $30.5 | $1.58 | -95% |
SNWV's yearly returns have swung widely, from +371% in 2024 to −81% in 2022. It's down 95% so far in 2026.